Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKGP.L Regulatory News (KGP)

  • There is currently no data for KGP

Interim Management Statement

10 Nov 2014 07:00

RNS Number : 5259W
Kingspan Group PLC
10 November 2014
 

Kingspan Group Plc

Interim Management Statement

 

10 November 2014

 

Kingspan Group plc, the global leader in high performance insulation and building envelopes, today issues the following Interim Management Statement, with trading information for the period from 1 July to 30 September 2014.

 

Sales in the nine month period to 30 September were €1.39bn, up 5% on the prior year (+5% constant currency). A solid sales performance was also recorded in the third quarter with revenue up 7% (+5% constant currency) compared to the same period in 2013.

Insulated Panels revenue in the first nine months increased by 9% (+9% constant currency), and by 8% (+7% constant currency) in the third quarter. The UK continued to perform well with encouraging activity across most building segments. After a sluggish second quarter sales performance, Mainland Europe remained weak through the third quarter reflecting somewhat of an abatement in German market activity. The pace of sales growth in North America improved in the third quarter helped by a strong order book as we entered the second half. Order intake also showed a significant improvement over prior year. Activity in Australasia continued the strong trend evident in the first half.

Insulation Board revenue in the first nine months was up 3% (+1% constant currency) compared with the same period last year, and ahead by 6% in quarter three (+2% constant currency). The UK sales performance was positive through the third quarter, and Mainland European sales were relatively stable overall year on year. Further progress in market conversion was evident in Australia during the third quarter.

Environmental revenue in the first nine months was ahead of last year by 1% (-2% constant currency) and by 3% (-3% constant currency) in the third quarter, continuing on the path of relative stabilisation seen earlier in the year.

Access Floors revenue in the first nine months was 4% behind the same period last year (-4% constant currency). Sales in the third quarter were ahead by 11% (+8% constant currency) with continuing momentum evident in UK office construction activity and an improvement in the US relative to a weak first half.

 Net debt at the end of September 2014 was €107.7m, €39.1m lower than at the same point in 2013. The fourth quarter is a seasonally cash generative period and this would indicate net debt levels by year end in the region of €140m after taking account of the acquisitions of Pactiv Insulation (North America) and PAL (UAE). These insulation board businesses were separately acquired in October for a combined consideration of €77m.The relative optimism that prevailed earlier in the year appears to have waned in recent months, particularly in Europe. Whilst our business continues to perform solidly, we nonetheless are mindful of what are currently more tempered 2015 economic forecasts, and remain focused on driving the Kingspan proposition, whatever the macro climate.

The fourth quarter of 2013 was particularly strong for the Group. Notwithstanding that, and with this seasonally important and often variable period to come, we expect to deliver a full-year trading profit in the region of €144m (+17% versus 2013).

 

For further information contact:

 

Gene Murtagh, Chief Executive Officer Tel: +353 (0) 42 9698000

 

Geoff Doherty, Chief Financial Officer Tel: +353 (0) 42 9698000

 

Douglas Keatinge, Murray Consultants Tel: +353 (0) 1 4980300

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDBGUGBGSR
Date   Source Headline
5th Apr 202212:49 pmRNSHolding(s) in Company
4th Apr 20229:51 amRNSHolding(s) in Company
1st Apr 20229:00 amRNSTotal Voting Rights
1st Apr 20227:00 amRNSHolding(s) in Company
30th Mar 20223:55 pmRNSDirector/PDMR Shareholding
28th Mar 20229:32 amRNSHolding(s) in Company
24th Mar 20226:09 pmRNSHolding(s) in Company
21st Mar 202212:00 pmRNSNotice of AGM
7th Mar 20226:06 pmRNSHolding(s) in Company
1st Mar 20227:00 amRNSTotal Voting Rights
24th Feb 20222:35 pmRNSDirector/PDMR Shareholding
24th Feb 20228:34 amRNSAnnual Financial Report
23rd Feb 20223:56 pmRNSDirector/PDMR Shareholding
18th Feb 20227:00 amRNSAcquisition
18th Feb 20227:00 amRNSFinal Results
27th Jan 20226:10 pmRNSHolding(s) in Company
27th Jan 20229:34 amRNSHolding(s) in Company
12th Jan 20225:01 pmRNSHolding(s) in Company
10th Jan 20223:22 pmRNSHolding(s) in Company
4th Jan 20229:00 amRNSBlock listing Interim Review
4th Jan 20228:00 amRNSTotal Voting Rights
9th Dec 202110:56 amRNSHolding(s) in Company
7th Dec 20214:15 pmRNSHolding(s) in Company
7th Dec 20219:17 amRNSHolding(s) in Company
1st Dec 20214:48 pmRNSTotal Voting Rights
22nd Nov 202110:14 amRNSHolding(s) in Company
8th Nov 20217:00 amRNSTrading Statement
1st Nov 20213:45 pmRNSTotal Voting Rights
6th Oct 202110:38 amRNSHolding(s) in Company
1st Oct 202111:17 amRNSTotal Voting Rights
1st Oct 202110:04 amRNSDirector Declaration
1st Oct 20219:23 amRNSHolding(s) in Company
10th Sep 20211:54 pmRNSDirector/PDMR Shareholding
8th Sep 20212:12 pmRNSDirector/PDMR Shareholding
1st Sep 202110:22 amRNSTotal Voting Rights
24th Aug 20212:49 pmRNSHolding(s) in Company
23rd Aug 20212:48 pmRNSDirector/PDMR Shareholding
20th Aug 20217:00 amRNSHalf-year Report
16th Aug 20219:53 amRNSHolding(s) in Company
22nd Jul 202110:42 amRNSHolding(s) in Company
7th Jul 20214:53 pmRNSHolding(s) in Company
6th Jul 20215:14 pmRNSHolding(s) in Company
6th Jul 20215:12 pmRNSHolding(s) in Company
1st Jul 202111:44 amRNSBlock listing Interim Review
1st Jul 202111:36 amRNSTotal Voting Rights
23rd Jun 20215:12 pmRNSHolding(s) in Company
22nd Jun 20217:00 amRNSTrading Statement
15th Jun 202112:49 pmRNSAcquisition Update
11th Jun 20216:36 pmRNSHolding(s) in Company
10th Jun 20215:35 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.